Skip to main content

Research Progress on the Anti-Rheumatoid Arthritis Drugs

  • Conference paper
  • First Online:
Proceedings of the 2012 International Conference on Applied Biotechnology (ICAB 2012)

Part of the book series: Lecture Notes in Electrical Engineering ((LNEE,volume 250))

  • 1834 Accesses

Abstract

Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease leading to synovial hyperplasia and a series of multisystem comorbidities. Permanent disability usually occurs in 20–30 % of untreated patients within 2–3 years of the disease. Therefore, it is important to diagnose the disease and initiate treatment as early as possible. The drug therapy plays an important role in maintaining a state of very low disease activity and slowing the progression of joint damage. Traditional drug therapy in RA is a pyramid approach, in which nonsteroidal anti-inflammatory drugs (NSAIDs) serve as the base of pyramid and disease-modifying antirheumatic drugs (DMARDs) are employed relatively late. But since this approach is no longer valid, many new drugs used to manage RA have been developed. In this review, we specifically summarize the current drug therapies for the treatment of RA and briefly describe the etiology, pathology and pathogenesis of RA.

The first two authors contributed equally to the project.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Harris ED (1990) Rheumatoid arthritis: pathophysiology and implications in therapy. New Eng J Med 322:1277–1289

    Article  Google Scholar 

  2. Carmona L, Cross M, Williams B et al (2010) Rheumatoid arthritis. Best Pract Res Clin Rheumatol 24:733–745

    Article  Google Scholar 

  3. Zvaifler NJ (1983) Pathogenesis of the joint disease of rheumatoid arthritis. Am J Med 75:3–8

    Article  CAS  Google Scholar 

  4. Smolen JS, Aletaha D, Redlich K (2012) The pathogenesis of rheumatoid arthritis: new insights from old clinical data? Nat Rev Rheumatol 8:235–243

    Article  CAS  Google Scholar 

  5. Gregersen PK (1999) Genetics of rheumatoid arthritis: confronting complexity. Arthritis Res 1:37–44

    Article  CAS  Google Scholar 

  6. Schuna AA (1998) Update on treatment of rheumatoid arthritis. J Am Pharm Assoc 38:728–735

    CAS  Google Scholar 

  7. Erhardt CC, Mumford PA, Venables PJ et al (1989) Factors predicting a poor life prognosis in rheumatoid arthritis: an eight year prospective study. Ann Rheum Dis 48:7–13

    Article  CAS  Google Scholar 

  8. Silman AJ, MacGregor AJ, Thomson W et al (1993) Twin concordance rates for rheumatoid arthritis: results from a nationwide study. Br J Rheumatol 32:903–907

    Article  CAS  Google Scholar 

  9. Vaughan JH, Kouri T, Petersen J et al (1988) On the etiology of rheumatoid arthritis. Scand J Rhetrmatol Suppl 74:19–28

    Article  CAS  Google Scholar 

  10. Gregersen PK, Silver J, Winchester RJ et al (1987) The shared epitope hypothesis: an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 30:1205–1213

    Article  CAS  Google Scholar 

  11. Stastny P (1978) Association of the B-cell alloantigen Dm4 with rheumatoid arthritis. N Engl J Med 298:869–871

    Article  CAS  Google Scholar 

  12. Ronnelid J, Lysholm J, Engstrom-Laurent et al (1994) Local anti-type II collagen antibody prodution in rheumatoid arthritis synovial fluid: evidence for an HLA-DR4-restricted IgG response. Arthritis Rheum 37:1023–1029

    Article  CAS  Google Scholar 

  13. Schiff B, Mizrachi Y, Orgad S et al (1982) Association of HLA-Aw31 and HLA-DR1 with rheumatoid arthritis. Ann Rheum Dis 41:403–404

    Article  CAS  Google Scholar 

  14. Woodrow JC, Nichol FE, Zaphiropoulos G (1981) DR antigens and rheumatoid arthritis: a study of two populations. Br Med J 283:1287–1288

    Article  CAS  Google Scholar 

  15. Goldring SR (2000) A 55-year-old woman with rheumatoid arthritis. JAMA2000 283:524–531

    Google Scholar 

  16. Scott PA, Kingsley GH, Smith CM et al (2007) Non-steroidal anti-inflammatory drugs and myocardial infarctions: Comparative systematic review of evidence from observational studies and randomised controlled trials. Ann Rheum Dis 66:1296–1304

    Article  CAS  Google Scholar 

  17. Schaffer D, Florin T, Eagle C et al (2006) Risk of serious NSAID-related gastrointestinal events during long-term exposure: a systematic review. Med J Aust 185:501–506

    Google Scholar 

  18. Donahue KE, Gartlehner G, Jonas DE et al (2008) Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med 148:124–134

    Article  Google Scholar 

  19. Kremer JM, Genovese MC, Cannon GW et al (2002) Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. Ann Intern Med 137:726–733

    Article  CAS  Google Scholar 

  20. Choy EH, Panayi GS (2001) Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344:907–916

    Article  CAS  Google Scholar 

  21. Lovell DJ, Giannini EH, Reiff A et al (2000) Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 342:763–769

    Article  CAS  Google Scholar 

  22. Moreland LW, Baumgartner SW, Schiff MH et al (1997) Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 337:141–147

    Article  CAS  Google Scholar 

  23. Weinblatt ME, Kremer JM, Bankhurst AD et al (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340:253–259

    Article  CAS  Google Scholar 

  24. Mohler KM, Torrance DS, Smith CA et al (1993) Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 151:1548–1561

    CAS  Google Scholar 

  25. Keystone EC, Kavanaugh AF, Sharp JT et al (2004) Radiographic, clinical, and functional outcomes of reatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 50:1400–1411

    Article  CAS  Google Scholar 

  26. Taylor PC, Steuer A, Gruber J et al (2002) Infliximab attenuates joint destruction in early RA patients with ultrasonographic markers of poor prognosis. Arthritis Rheum 46:334

    Google Scholar 

  27. Fishwild DM, O’Donnell SL, Bengoechea T et al (1996) High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice. Nat Biotechnol 14:845–851

    Article  CAS  Google Scholar 

  28. Kremer J, Ritchlin C, Mendelsohn A et al (2010) Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: forty-eightweek efficacy and safety results of a phase III randomized, double- blind, placebocontrolled study. Arthritis Rheum 62:917–928

    Article  CAS  Google Scholar 

  29. Nesbitt A, Fossati G, Bergin M et al (2007) Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis 13:1323–1332

    Article  Google Scholar 

  30. Gomez-Reino JJ, Fairfax MJ, Pavelka K et al (2007) Targeted inhibition of IL-6 with tocilizumab improves quality of life and function in patients with rheumatoid arthritis with inadequate response to a range of DMARDs. Arthritis Rheum 56:4234

    Google Scholar 

  31. Genovese M, McKay J, Nasonov E et al (2007) IL-6 receptor inhibition with tocilizumab reduces disease activity in patients with rheumatoid arthritis with inadequate response to a range of DMARDs: the TOWARD Study. Arthritis Rheum 56:4309–4310

    Google Scholar 

  32. Dass S, Vital EM, Emery P (2006) Rituximab: novel B-cell depletion therapy for the treatment of rheumatoid arthritis. Expert Opin Pharmacother 7:2559–2570

    Article  CAS  Google Scholar 

  33. Moreland LW, Alten R, Van den Bosch F et al (2002) Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum 46:1470–1479

    Article  CAS  Google Scholar 

  34. Emery P (2003) The therapeutic potential of costimulatory blockade with CTLA-4Ig in rheumatoid arthritis. Expert Opin Investig Drugs 12:673–681

    Article  CAS  Google Scholar 

  35. Kirwan JR, Bijlsma JW, Boers M et al (2007) Effects of glucocorticoids on radiological progression in rheumatoid arthritis. The Cochrane Libr doi: 10.1002/s14651858006356

  36. Bijlsma JW, van der Goes MC, Hoes JN et al (2010) Lowdose glucocorticoid therapy in rheumatoid arthritis: an obligatory therapy. Ann N Y Acad Sci 1193:123–126

    Article  CAS  Google Scholar 

  37. Little C, Parsons T (2000) Herbal therapy for treating rheumatoid arthritis. The Cochrane Libr. doi:10.1002/s14651858002948

    Google Scholar 

  38. Alarcon GS (2000) Tetracyclines for the treatment of rheumatoid arthritis. Expert Opin Investig Drugs 97:1491–1498

    Article  Google Scholar 

Download references

Acknowledgments

This study was financially supported by the Program for Changjiang Scholars and Innovative Research Team in University of Ministry of Education of China (NO. IRT1166).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Tong-Cun Zhang .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Wang, P., Luo, X., Wang, C., Wang, X., Hu, G., Zhang, TC. (2014). Research Progress on the Anti-Rheumatoid Arthritis Drugs. In: Zhang, TC., Ouyang, P., Kaplan, S., Skarnes, B. (eds) Proceedings of the 2012 International Conference on Applied Biotechnology (ICAB 2012). Lecture Notes in Electrical Engineering, vol 250. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-37922-2_94

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-37922-2_94

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-37921-5

  • Online ISBN: 978-3-642-37922-2

  • eBook Packages: EngineeringEngineering (R0)

Publish with us

Policies and ethics